Arnold Demain

Edit links
Source: Wikipedia, the free encyclopedia.
Arnold L. Demain
Born(1927-04-26)April 26, 1927
MIT, Drew University

Arnold L. Demain (April 26, 1927 – April 3, 2020) was an American

Merck & Co. The August 2010 edition of The Journal of Antibiotics celebrated his scientific career.[3] Demain was described as "one of the world's leading industrial microbiologists" and as "a scientist constantly in the forefront of industrial microbiology and biotechnology." He was "a pioneer in research on the elucidation and regulation of the biosynthetic pathways leading to the penicillins and cephalosporins" and "instrumental in the development of the beta-lactam industry". One feature of Demain's work, according to Microbiology Australia, was his "ability to undertake fundamental research on systems with clear industrial applications, recognising that biodiscovery is the start of the road that includes strain improvement to achieve levels of product synthesis that warrant further investment to take products into the marketplace."[4][5]

Demain published over 500 papers, co-edited or co-authored fourteen books, and took out 21 U.S. patents.[4][5]

Early life and education

Demain was born in

Bronx, and graduated high school at age 16.[4][6][7]

Demain attended Michigan State briefly, then joined the

U.S. Navy in 1945 and spent two years in Philadelphia caring for amputees who were members of the armed forces who had been injured in the war. Demain returned to Michigan State in 1947, earning B.S. and M.S. degrees in bacteriology from the Department of Microbiology and Public Health in 1949 and 1950 respectively. His master's research topic was the spoilage and softening of pickles during fermentation, a phenomenon that, he concluded, was probably caused by pectic enzymes.[6][7] At MSC Demain met and married a fellow student, Joanna ("Jody") Kaye from Youngstown, Ohio.[6]

From MSC, Demain went to the University of California's Department of Food Science, which was first at the Berkeley campus and then at Davis working with Herman Phaff. He began work on his Ph.D. project on polygalacturonase of Saccharomyces fragilis. The project resulted in four papers on pectic enzymes, one of which published in Nature.[4] At Berkeley, he was in charge of the cultures in UC's yeast collection. Demain said that he and Phaff "apparently were the first in the world to carry out affinity chromatography, using a pectic acid gel to selectively adsorb YPG from culture filtrates."[6] Demain received his Ph.D. in 1954.[7]

Career

In early 1954, Demain moved to Danville, Pennsylvania, where he worked as a research microbiologist for Merck Sharp & Dohme, studying the synthesis of penicillin. His work helped identify the

amino acids that form the nucleus of penicillin, established the mechanisms that enable primary metabolites and carbon sources to regulate secondary metabolite synthesis, and demonstrated that penicillin was the product of synthesis and inactivation during fermentation.[4][6] In late 1955, Demain moved on to Merck's penicillin research laboratories in Rahway, New Jersey, where he worked on fermentation microbiology, â-lactam antibiotics, flavor nucleotides, and microbial nutrition.[7]

In 1964 when he was asked to form a new department at Merck that would involve the improvement of product biosynthesis in microbial strains.[6] Demain named it the Department of Fermentation Microbiology[6] Demain "directed research and development on processes for monosodium glutamate, vitamin B12, streptomycin, riboflavin, cephamycin, fosfomycin, and interferon inducers,"[7] and "elucidated the mechanism by which the biosynthesis of cephalosporin in Cephalsporium acremonium was stimulated by the presence of methionine – a new mechanism which had not been reported before." The team managed to boost production yields of vitamin B12.[6] The work done under Demain's direction in Rahway has been described in Microbiology Australia as "remarkable" in its "level of innovation," in that it identified "novel biochemical pathways" that improved "natural levels of production" several thousandfold.[4]

In 1968, Demain was invited by

Nevin Scrimshaw, head of the Department of Nutrition and Food Science at the Massachusetts Institute of Technology,[8] to become a full professor at that university. The next year Demain became Professor of Industrial Microbiology in Scrimshaw's department at MIT and set up a fermentation microbiology laboratory there. Demain stayed at MIT for the next 32 years. In 1970, Demain went to Prague to present the closing Plenary Session address at the first Genetics of Industrial Microorganisms Symposium. He spoke on the "marriage of genetics and industrial microbiology."[4]

At MIT, Demain and his team pioneered research on the elucidation and regulation of the biosynthetic pathways leading to penicillins and cephalosporins.[4][5] Demain's MIT research led to "a breakthrough discovery of a key enzyme in cephalosporin biosynthesis –deacetoxycephalosporin C synthetase ('expandase'). The discovery of this enzyme established the role of penicillin as an intermediate in cephalosporin C biosynthesis and disproved the previous hypothesis that these two separate end products of C. acremonium were formed by a branched secondary metabolic pathway."[citation needed]

In the mid-1990s, Demain and his team "started a series of NASA-sponsored experiments to determine the effect of simulated microgravity (SMG) on secondary metabolism" and "found that regulation of microbial processes under SMG was quite different from that at normal gravity." In his last MIT projects he studied Clostridium tetani and C. difficile with the aim of facilitating the production of improved tetanus and antibiotic-associated diarrhea vaccines. The effort was successful.[6] Summing up his years at MIT, Demain later said that he "was very lucky...to have had a fantastic group of bright and hardworking visiting scientists, postdoctoral associates, graduate students, undergraduate students and high school students. I owe all my success to them and my two amazing lab supervisors, Nadine A. Solomon and Aiqi Fang....Success at MIT would not have been possible without them."[6]

Demain has said that "the explosion of the biotechnology field" in the early 1970s led to his involvement with "the first biotechnology company, the Cetus Corporation, in Berkeley in 1971." Demain became an advisor to Cetus.[6]

In 2001, Demain became one of a small group of Research Fellows pwcat the Charles Dana Research Institute for Scientists Emeriti, or RISE, at Drew University in New Jersey. In this capacity he trained undergraduate students in conducting research in microbial chemistry.[4][5]

Other professional activities

Demain was elected president of the Society for Industrial Microbiology in 1990, and became a member of the

People's Republic of China.[4] In addition, he was a member of the scientific advisory boards of Tetravitae Bioscience and of Dyadic International, and was also on the advisory board of Codexis, Inc.[9][10]

Honors and awards

Demain has received honorary doctorates from the

Technion (Israel), Michigan State, and University of Münster (Germany).[4] The August 2010 special issue of The Journal of Antibiotics celebrated Demain's career, noting that he had "established and maintained a renowned reputation within the field of industrial microbiology."[11]

Personal life

Arny Demain was married to Joanna (Kaye) Demain for 68 years; they had two children, Pamela and Jeffrey. He died from complications of COVID-19.[12]

References

  1. doi:10.1089/ind.2006.2.239
    .
  2. S2CID 32313749
    .
  3. ^ "Dr. Arnold Demain – 60 years in a scientific career : The Journal of Antibiotics".
  4. ^ a b c d e f g h i j k "A Tribute to Professor Arnold L Demain – a lifetime in industrial microbiology". Microbiology Australia.
  5. ^ a b c d "Arnold L. Demain". SemGen. Archived from the original on 2013-11-11. Retrieved 2013-11-11.
  6. ^
    S2CID 32313749
    .
  7. ^ a b c d e "BIT's 6th Life Spring Forum" (PDF). Drew.edu.
  8. ^ "Nevin S. Scrimshaw, Ph.D., M.D., M.P.H". International Nutrition Foundation. 22 July 2023.
  9. ^ "Codexis Announces Appointment of Dr. Arnold Demain to Industrial Advisory Board". PR Newswire.
  10. ^ "Arnold Demain Ph.D". Businessweek. 27 October 2023.[dead link]
  11. ^ "DR. ARNOLD DEMAIN – 60 YEARS IN A SCIENTIFIC CAREER". The Journal of Antibiotics.
  12. ^ Raleigh McElvery (14 April 2020). "Professor Emeritus Arnold Demain, a pioneer in the development of antibiotics, dies at 92". MIT.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Arnold_Demain&oldid=1195927044"